Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Nov;24(8):1042-1050.
doi: 10.1111/papr.13399. Epub 2024 Jul 2.

Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: Secondary analyses by baseline pain intensity and use of rescue medication of a phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial

Affiliations
Clinical Trial

Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: Secondary analyses by baseline pain intensity and use of rescue medication of a phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial

Eugene R Viscusi et al. Pain Pract. 2024 Nov.

Abstract

Background: In the randomized, phase 3, SUSA-301 trial, celecoxib-tramadol co-crystal (CTC) provided significantly greater analgesia compared with celecoxib, tramadol, or placebo in adults with acute, moderate-to-severe, postoperative pain. This post hoc, secondary analysis further evaluated the use of rescue medication and the incidence of treatment-emergent adverse events (TEAEs).

Methods: Patients (N = 637) were randomized 2:2:2:1 to receive oral CTC 200 mg twice daily (BID; n = 184), tramadol 50 mg four times daily (QID; n = 183), celecoxib 100 mg BID (n = 181), or placebo QID (n = 89). Post hoc analyses were conducted on the use of rescue medications up to 4 and 48 h post-study drug dose, stratified by baseline pain intensity (moderate/severe), and on the incidence of TEAEs, stratified by rescue medication use.

Results: A significantly lower proportion of patients received any rescue medication within 4 h post-study dose with CTC (49.5%) versus tramadol (61.7%, p = 0.0178), celecoxib (65.2%, p = 0.0024), and placebo (75.3%, p = 0.0001); this was also seen for oxycodone use. Fewer patients in the CTC group received ≥3 doses of rescue medication compared with the other groups, irrespective of baseline pain intensity. In patients who did not receive opioid rescue medication, CTC was associated with a lower incidence of nausea and vomiting TEAEs versus tramadol alone. In patients who received rescue oxycodone, the incidence of nausea was similar in the CTC and tramadol groups, and higher versus celecoxib and placebo.

Conclusion: Celecoxib-tramadol co-crystal was associated with reduced rescue medication use and an acceptable tolerability profile compared with tramadol or celecoxib alone in adults with acute, moderate-to-severe, postoperative pain.

Keywords: acute pain; analgesia; anti‐inflammatory agents—non‐steroidal; celecoxib; co‐crystal; joint pain; postoperative pain; tramadol.

PubMed Disclaimer

References

REFERENCES

    1. Langford R, Margarit C, Morte A, Cebrecos J, Sust M, Ortiz E, et al. Co‐crystal of tramadol–celecoxib (CTC) for acute moderate‐to‐severe pain. Curr Med Res Opin. 2024;40:455–468.
    1. Kowa Pharmaceuticals America Inc. Seglentis: US prescribing information. 2021. Accessed 26 June 2023. Available from: https://www.kowapharma.com/documents/SEGLENTIS_Prescribing_Information.pdf.
    1. Viscusi ER, de Leon‐Casasola O, Cebrecos J, Jacobs A, Morte A, Ortiz E, et al. Celecoxib‐tramadol co‐crystal in patients with moderate‐to‐severe pain following bunionectomy with osteotomy: a phase 3, randomized, double‐blind, factorial, active‐ and placebo‐controlled trial. Pain Pract. 2023;23:8–22.
    1. Esteve Pharmaceuticals SA. Esteve announces FDA approval of a novel co‐crystal form of celecoxib and tramadol for the management of acute pain. 2021. Accessed 3 May 2023. Available from: https://www.esteve.com/uk/news/esteve‐announces‐fda‐approval‐of‐a‐novel‐....
    1. Esteve Pharmaceuticals SA. Velyntra Spanish regulatory approval. 2023. Accessed 9 Oct 2023. Available from: https://cima.aemps.es/cima/dochtml/ft/89051/FT_89051.html.

Publication types

MeSH terms

LinkOut - more resources